<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8F5430F8-D819-4EE8-9D2B-513E701178AF"><gtr:id>8F5430F8-D819-4EE8-9D2B-513E701178AF</gtr:id><gtr:name>Immune Design</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/017349DC-94C2-4AB9-AAD6-7E6813B6DC64"><gtr:id>017349DC-94C2-4AB9-AAD6-7E6813B6DC64</gtr:id><gtr:name>PaxVax, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/ED9688EB-63CD-48F5-8C4C-1C812B0955AD"><gtr:id>ED9688EB-63CD-48F5-8C4C-1C812B0955AD</gtr:id><gtr:name>MediTox s.r.o.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1E227415-0DCC-48DC-B2DA-CB325D7515FD"><gtr:id>1E227415-0DCC-48DC-B2DA-CB325D7515FD</gtr:id><gtr:name>US Dept of Energy</gtr:name><gtr:address><gtr:line1>1000 Independence Avenue</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F0218A50-2D74-431E-9B66-7B583688A24A"><gtr:id>F0218A50-2D74-431E-9B66-7B583688A24A</gtr:id><gtr:name>Kumamoto University</gtr:name><gtr:address><gtr:line1>Kumamoto University</gtr:line1><gtr:line2>Honjo 1-1-1</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BEC1113E-4ECC-4F45-A8F9-7147AB4776FF"><gtr:id>BEC1113E-4ECC-4F45-A8F9-7147AB4776FF</gtr:id><gtr:name>Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/70713789-B41C-4730-A26D-B92DD613858D"><gtr:id>70713789-B41C-4730-A26D-B92DD613858D</gtr:id><gtr:name>IDT Biologika GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB"><gtr:id>CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB</gtr:id><gtr:name>HIV Vaccine Trials Network, USA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/256263C2-5AC3-45D3-94FC-75ADED14042E"><gtr:id>256263C2-5AC3-45D3-94FC-75ADED14042E</gtr:id><gtr:name>The Clinical Biomanufacturing Facility (CBF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30326D2E-953D-4CE9-9350-309A797BD01C"><gtr:id>30326D2E-953D-4CE9-9350-309A797BD01C</gtr:id><gtr:name>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/127B6EB3-CF02-42A1-9B3A-9A45D8E9B0E0"><gtr:id>127B6EB3-CF02-42A1-9B3A-9A45D8E9B0E0</gtr:id><gtr:name>European AIDS Vaccine Initiative 2020 (EAVI2020)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Central Admin - Research Services</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8F5430F8-D819-4EE8-9D2B-513E701178AF"><gtr:id>8F5430F8-D819-4EE8-9D2B-513E701178AF</gtr:id><gtr:name>Immune Design</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/017349DC-94C2-4AB9-AAD6-7E6813B6DC64"><gtr:id>017349DC-94C2-4AB9-AAD6-7E6813B6DC64</gtr:id><gtr:name>PaxVax, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/ED9688EB-63CD-48F5-8C4C-1C812B0955AD"><gtr:id>ED9688EB-63CD-48F5-8C4C-1C812B0955AD</gtr:id><gtr:name>MediTox s.r.o.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1E227415-0DCC-48DC-B2DA-CB325D7515FD"><gtr:id>1E227415-0DCC-48DC-B2DA-CB325D7515FD</gtr:id><gtr:name>US Dept of Energy</gtr:name><gtr:address><gtr:line1>1000 Independence Avenue</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F0218A50-2D74-431E-9B66-7B583688A24A"><gtr:id>F0218A50-2D74-431E-9B66-7B583688A24A</gtr:id><gtr:name>Kumamoto University</gtr:name><gtr:address><gtr:line1>Kumamoto University</gtr:line1><gtr:line2>Honjo 1-1-1</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BEC1113E-4ECC-4F45-A8F9-7147AB4776FF"><gtr:id>BEC1113E-4ECC-4F45-A8F9-7147AB4776FF</gtr:id><gtr:name>Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/70713789-B41C-4730-A26D-B92DD613858D"><gtr:id>70713789-B41C-4730-A26D-B92DD613858D</gtr:id><gtr:name>IDT Biologika GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB"><gtr:id>CBCD41ED-035C-40C2-BD4E-17CC8D2DB4AB</gtr:id><gtr:name>HIV Vaccine Trials Network, USA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/256263C2-5AC3-45D3-94FC-75ADED14042E"><gtr:id>256263C2-5AC3-45D3-94FC-75ADED14042E</gtr:id><gtr:name>The Clinical Biomanufacturing Facility (CBF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30326D2E-953D-4CE9-9350-309A797BD01C"><gtr:id>30326D2E-953D-4CE9-9350-309A797BD01C</gtr:id><gtr:name>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/127B6EB3-CF02-42A1-9B3A-9A45D8E9B0E0"><gtr:id>127B6EB3-CF02-42A1-9B3A-9A45D8E9B0E0</gtr:id><gtr:name>European AIDS Vaccine Initiative 2020 (EAVI2020)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A9A12AFB-52DD-481B-A639-8F98B1C69AA1"><gtr:id>A9A12AFB-52DD-481B-A639-8F98B1C69AA1</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>McMichael</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DE3AB9E4-468F-4A59-9D72-9C7ADF27B92F"><gtr:id>DE3AB9E4-468F-4A59-9D72-9C7ADF27B92F</gtr:id><gtr:firstName>Benedikt</gtr:firstName><gtr:otherNames>Mathias</gtr:otherNames><gtr:surname>Kessler</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8B063DF8-CBFF-4B1C-BE0C-60F2F7CF71D8"><gtr:id>8B063DF8-CBFF-4B1C-BE0C-60F2F7CF71D8</gtr:id><gtr:firstName>Tomas</gtr:firstName><gtr:surname>Hanke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001757"><gtr:id>ABE603FA-4DB0-4E35-8BEA-086B90F5E55E</gtr:id><gtr:title>A universal T cell vaccine for HIV-1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001757</gtr:grantReference><gtr:abstractText>HIV infection and AIDS continues to spread in a virtually uncontrolled manner. The best and possibly only hope to change this alarming situation is a safe, effective, accessible protective vaccine. Arguably the biggest challenge in developing such a vaccine is enormous HIV variability, which dwarfs that of almost any other infection. However, all parts of the virus cannot easily change. To remain alive, HIV has to keep some smaller regions of its proteins more or less constant. We have taken an advantage of this and constructed a candidate vaccine designed specifically to overcome HIV variability by focusing the body defences on the conserved regions of the virus, i.e. the Achilles heel of HIV. Here, we are proposing to build on and extend our ongoing vaccine development effort and, if successful, assemble a strong case for further evaluation of this vaccination strategy in larger scale and expensive field efficacy studies.</gtr:abstractText><gtr:technicalSummary>The best solution to the HIV/AIDS epidemic is development of an effective prophylactic vaccine. T cell stimulating vaccines offer a realistic alternative, or supplement to, antibody inducing vaccines. The latter are proving extremely difficult to generate and T cell stimulating vaccines, while not preventing infection, do ameliorate disease in monkey/SIV models. However, virus variability is a major problem resulting in poor recognition of infecting virus and easy escape of virus from early T cell control. These issues could be avoided by focusing vaccine-induced T cell responses on conserved regions of HIV-1. While most patients with chronic HIV-1 infection do make some T cell responses to conserved regions, these responses are usually weak (subdominant) and, like broadly neutralizing antibody responses, develop too late in the infection to provide real benefit. We have constructed immunogen HIVconsv, which is derived from the 14 least variable HIV-1 segments and contains over 200 epitopes, and have shown that it stimulates strong T cell responses in mice and in rhesus macaques. Phase I clinical trials in Oxford evaluating safety and immunogenicity of three HIVconsv vaccines delivered as plasmid DNA, recombinant MVA and recombinant chimpanzee adenovirus have started.
 Here, we shall further refine the vaccine design to improve the prototype immunogen, vaccine vectors and their formulation. We shall test different vaccination regimens to maximize T cell induction and assess surrogate efficacy in inbred and outbred mice. We shall make a second ?mosaic? immunogen complementing HIVconsv, which will improve perfect matching of amino acids to HIV-1 variants from clades A,B,C and D from 72% to 90%. We shall study in depth vaccine-induced responses in humans, looking at how well the known conserved (but often subdominant in HIV-1 infection) epitopes are presented by antigen-presenting cells exposed to these constructs. We shall examine how efficiently the HIVconsv-specific T cells recognize and kill HIV-1-infected cells. We shall employ state-of-the-art proteomics (tandem MS/nanoflow RPLC) to obtain a comprehensive picture of conserved region peptide processing and presentation on the cell surface, and comparing epitope presentation from the HIVconsv vaccines and HIV-1. This will indicate whether the HIVconsv needs further optimization.
 Results generated from this programme together with our complementing, separately funded components (non-human primate and human trials) will be key in assessing the suitability of conserved region T cell vaccines for efficacy trials in high-risk human cohort(s), either alone or with an antibody-based vaccine.</gtr:technicalSummary><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1322813</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Assessment of tHIVconsvX-specific responses in HIV-positive patients</gtr:description><gtr:id>AEE99439-F6E8-4649-97F6-5418B929D4D8</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Testing of peptides in HIV-1-positive patients</gtr:partnerContribution><gtr:piContribution>Design and provision of tHIVconsvX peptides</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MediTox s.r.o.</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>215F5627-F77C-41DE-B9BE-03F68CF60595</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Impact of mosaic design on T cell response cloncality</gtr:description><gtr:id>AF38D6D0-1D30-4D97-A38D-A731C76D1703</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Tetramer sorting of immune mouse splenocytes and T cell receptor analysis</gtr:partnerContribution><gtr:piContribution>Vaccine construction, immunisation of mice and T cell assays, tetramer design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adjuvantation by PIV5 DI particles</gtr:description><gtr:id>3A69BDD3-C4CD-4F68-A09A-77A2417729CF</gtr:id><gtr:impact>Multidisciplinary, we shall aim to publish our results.</gtr:impact><gtr:partnerContribution>Provision of PIV5 DI particles</gtr:partnerContribution><gtr:piContribution>Adjuvantation by PIV5 DI particles will be evaluated in mice. We shall use our candidate HIVconsv vaccines and carry out the experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IDT Biologika GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>GMP manufacture of MVA.tHIVconsv3 and MVA.tHIVconsv4</gtr:description><gtr:id>8E06D14B-8A31-466D-8434-EF9B613DEDE6</gtr:id><gtr:impact>When completed, clinical lots of two experimental vaccines</gtr:impact><gtr:partnerContribution>IDT is the manufacturing house
IAVI paid for one rMVA</gtr:partnerContribution><gtr:piContribution>Manufacture of two vaccines for clinical trial use</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European AIDS Vaccine Initiative 2020 (EAVI2020)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>European AIDS Vaccine Initiative 2020 (EAVI2020)</gtr:description><gtr:id>378209EE-F23A-4885-BD82-C148181B6192</gtr:id><gtr:impact>It is work in progress

www.eavi2020.eu
Twitter www.twitter.com/eavi2020
Like us on Facebook: www.facebook.com/eavi2020
LinkedIn: www.linkedin.com/company/eavi2020
ResearchGate: https://www.researchgate.net/profile/Eavi_2020</gtr:impact><gtr:partnerContribution>Our partners will provided preclinical and Experimental Medicine research, their candidate HIV vaccines and their expertise</gtr:partnerContribution><gtr:piContribution>We shall provided preclinical and Experimental Medicine research, our conserved mosaic HIV vaccines and our expertise</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Determination of binding affinities of peptides for HLA</gtr:description><gtr:id>08CFB00D-6569-49D3-A6F5-8FE90D1AA248</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:partnerContribution>HLA affinity assay</gtr:partnerContribution><gtr:piContribution>Peptide identification and provision</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>3F63647B-F6B5-48C4-8CB2-1DABECACEDC1</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Weill Cornell Medical College</gtr:department><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>EEBEB5FF-F70E-4576-A84E-F069473C33B3</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>HLA associated peptidome characterization</gtr:description><gtr:id>CA4BB934-4C57-40BB-870C-311943BC737B</gtr:id><gtr:impact>Multi-disciplinary collaboration resulting in a publication</gtr:impact><gtr:partnerContribution>expertise in rheumatilogy</gtr:partnerContribution><gtr:piContribution>Methodology for eluting and identifying HLA-associated peptidome</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kumamoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Analysis of T cell responses in antiretroviral treatment-naive patients</gtr:description><gtr:id>8FFEDD0D-ABDE-42BE-9234-8D9D5E95442E</gtr:id><gtr:impact>Multidisciplinary, publications out and in preparation</gtr:impact><gtr:partnerContribution>Measurements of T cell responses and HIV viral load in treatment-naive patients and correlation of magnitude and breadth of responses with viral load and CD4 cell counts
Determination of HLA-restriction of mapped epitopes</gtr:partnerContribution><gtr:piContribution>Identification of conserved regions and provision of corresponding peptides
Identification and mapping of conserved region vaccine elicited epitopes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sir William Dunn School of Pathology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Central Proteomic Facility</gtr:department><gtr:description>LC-MS/MS</gtr:description><gtr:id>D737618F-A339-4404-A18F-10736801389E</gtr:id><gtr:impact>Multidisciplinary, ongoing, publications anticipated.</gtr:impact><gtr:partnerContribution>Know-how and equipment.</gtr:partnerContribution><gtr:piContribution>The aim is to analyze the HLA-associated peptidome on HIV or HIVconsv expressing cells.
Post-doctoral scientist and some key reagents.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Clinical trial HIV-CORE 001, 002, 003, 004 and RIVER, BCN01, BCN02 and PEACHI-04 volunteers</gtr:description><gtr:id>55FB6A61-D7C0-4692-BC0B-F111D4812B19</gtr:id><gtr:impact>Safety and immunogenicity data on the MVA.HIVconsv vaccine.</gtr:impact><gtr:partnerContribution>Lucy Dorrell will provide a cohort of HIV-1-infected patients and carry out clinical trial evaluating safety and immunogenicity the MVA.HIVconsv vaccine.</gtr:partnerContribution><gtr:piContribution>Providing GMP vaccines, expertise and input on trial design and immunological analysis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GMP manufacture of ChAdOx1.tHIVconsv5 and ChAdOx1.tHIVconsv6</gtr:description><gtr:id>00EF660E-B6BA-47CF-928E-D53E0702173A</gtr:id><gtr:impact>Clinical batches of two vaccines will be produced</gtr:impact><gtr:partnerContribution>CBF will manufacture the vaccine
IAVI provided the funds for one vaccine</gtr:partnerContribution><gtr:piContribution>Manufacture of two experimental vaccines for clinical use</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>HIVconsv vaccine development</gtr:description><gtr:id>A4A8EA39-8E6E-422F-A38A-D3AFA0FEF55F</gtr:id><gtr:impact>Clinical trial, optimizing vaccine delivery pre-clinically</gtr:impact><gtr:partnerContribution>Contribution towards running of trial HIV-CORE 004
1-year post-doc plus expenses</gtr:partnerContribution><gtr:piContribution>Developed vaccine strategy, got funding from EDCTP</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clinical trial HIV-CORE 001, 002, 003, 004 and RIVER, BCN01, BCN02 and PEACHI-04 volunteers</gtr:description><gtr:id>27F31816-4ECF-4311-965A-9DA615D54202</gtr:id><gtr:impact>Safety and immunogenicity data on the MVA.HIVconsv vaccine.</gtr:impact><gtr:partnerContribution>Lucy Dorrell will provide a cohort of HIV-1-infected patients and carry out clinical trial evaluating safety and immunogenicity the MVA.HIVconsv vaccine.</gtr:partnerContribution><gtr:piContribution>Providing GMP vaccines, expertise and input on trial design and immunological analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Human Immunology Laboratory, ICL</gtr:department><gtr:description>Sample evaluation in HIL reference laboratory</gtr:description><gtr:id>FF3F98D6-A550-4101-B110-8D11E88D1812</gtr:id><gtr:impact>The results will likely be part of publication describing immunogenicity of the HIVconsv vaccines tested in HIV-CORE002. Comparative data with other vaccine strategies.</gtr:impact><gtr:partnerContribution>IFN-y ELISPOT assays comparative with other HIV vaccine candidates tested by IAVI and others</gtr:partnerContribution><gtr:piContribution>Frozen PBMC samples from clinical trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Einstein College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Construction of rBCG for delivery of conserved mosaic vaccines</gtr:description><gtr:id>0B3F1D47-C0E8-42E1-8AFD-48DB52D32804</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Construct rBCG and provide sufficient stocks for preclinical studies</gtr:partnerContribution><gtr:piContribution>We provide gene for conserved mosaic HIV vaccine and shall conduct pre-clinical immunogenicity studies in mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIV Vaccine Trials Network, USA</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Sample evaluation at HVTN</gtr:description><gtr:id>9383305B-16BE-4A2E-906A-7E905B5E09FE</gtr:id><gtr:impact>Comparative data with other vaccine strategies.</gtr:impact><gtr:partnerContribution>Know-how, evaluation of samples in standardized, reference assays.</gtr:partnerContribution><gtr:piContribution>We have provided samples from clinical trial HIV-CORE002 and peptides.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immune Design</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Construction and testing of Retrovirus-vectored tHIVconsvX vaccines</gtr:description><gtr:id>D7922338-EBA3-4DEE-9AD6-D83B2CFE1AC1</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Construction of two candidate vaccines.</gtr:partnerContribution><gtr:piContribution>Provision of 2 tHIVconsvX genes and preclinical testing of candidate vaccines.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Construction of MVA.HIVACAT-T for pre-clinical and clinical testing</gtr:description><gtr:id>E614BB42-948C-43ED-A34F-796107617595</gtr:id><gtr:impact>Publication submitted</gtr:impact><gtr:partnerContribution>Design of HIVACAT-T immunogen, preclinical testing in mice and monkeys.

GMP manufacture</gtr:partnerContribution><gtr:piContribution>Construction of candidate HIV vaccine MVA.HIVACAT-T carrying a IRSICAIXA-designed T cell immunogen

Advice on GMP manufacture</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Induction of HIV neutralizing antibodies</gtr:description><gtr:id>7204A521-22EB-4A35-8FCD-D5826FB04EAD</gtr:id><gtr:impact>Studies with BG505 uncleaved - Publication

Studies with BG505 SOSIP - In progress</gtr:impact><gtr:partnerContribution>WCMC - provision or trimeric gp140 BG505 SOSIP protein immunogen
IAVI - proviion of gp120 HBG505 unlceaved immunogen
Sir Willima Dunn Schol of Pathology - quality control and research assays for characterisation of vector-expressed Ev immunogen
Meditox - rabbit immunization study</gtr:partnerContribution><gtr:piContribution>We are developing heterologous prime-boost immunisation regimen delivering a highly promising HIV Env BG505 uncleaved or as SOSIP for induction of HIV neutralising antibodies.

Also we are developing regimens for efficient induction of T cell and B cell responses in parallel.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>U.S. Department of Energy</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Los Alamos National Laboratory</gtr:department><gtr:description>Development of a conserved mosaic protein as an immunogen</gtr:description><gtr:id>FF045FA2-D3D3-4E2C-B705-DF517A1DA018</gtr:id><gtr:impact>Early days</gtr:impact><gtr:partnerContribution>Providing an expertise in designing a vaccine immunogen</gtr:partnerContribution><gtr:piContribution>We describe what immunogen we would like to design and LANL used their computational power to design this immunogen. We then construct it and develop it</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Impact of mosaic design on T cell response cloncality</gtr:description><gtr:id>AD665239-C970-4470-B658-28012388C637</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Tetramer sorting of immune mouse splenocytes and T cell receptor analysis</gtr:partnerContribution><gtr:piContribution>Vaccine construction, immunisation of mice and T cell assays, tetramer design</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>U.S. Department of Energy</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Los Alamos National Laboratory</gtr:department><gtr:description>Design of 2nd generation tHIVconsvX vaccines</gtr:description><gtr:id>B11DE541-97DB-46BE-ACFF-FBC96F4F8CA4</gtr:id><gtr:impact>2nd generation vaccine - so far pre-clinical grade constructed

A joint Patent between UOXF/ISIS and LANL</gtr:impact><gtr:partnerContribution>Designed the 2 mosaics used and helped to select the conserved regions oh the HIV -1 proteome</gtr:partnerContribution><gtr:piContribution>Computer design of the 2nd generation conserved T cell immunogens tHIVconsvX</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>U.S. Department of Energy</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Los Alamos National Laboratory</gtr:department><gtr:description>Impact of mosaic design on T cell response cloncality</gtr:description><gtr:id>D7FDE806-C60B-4C31-9889-E0842F6EE24D</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Tetramer sorting of immune mouse splenocytes and T cell receptor analysis</gtr:partnerContribution><gtr:piContribution>Vaccine construction, immunisation of mice and T cell assays, tetramer design</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oregon Health and Science University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Development of RhCMV-vectored conserved region vaccines</gtr:description><gtr:id>CD671716-637E-46D3-A6FF-654CCAFED623</gtr:id><gtr:impact>Work in progress</gtr:impact><gtr:partnerContribution>Louis PIcker and Scott Hansen constructed RhCMV-vectored vaccines expressing SIVconsv239 and SIVconsvE660, immunized 16 rhesus macaques and will challenge them with SIVmac239</gtr:partnerContribution><gtr:piContribution>We provided SIV equivalents of our human conserved region mosaic immunogen (SIVconsv239 and SIVconsvE660) genes and vaccines expressing the same immunogens from ChAdOx1 and MVA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Clinical Biomanufacturing Facility (CBF)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GMP manufacture of ChAdOx1.tHIVconsv5 and ChAdOx1.tHIVconsv6</gtr:description><gtr:id>AA4B0810-CEE9-4B06-BE34-AA8F3560E5E2</gtr:id><gtr:impact>Clinical batches of two vaccines will be produced</gtr:impact><gtr:partnerContribution>CBF will manufacture the vaccine
IAVI provided the funds for one vaccine</gtr:partnerContribution><gtr:piContribution>Manufacture of two experimental vaccines for clinical use</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Human Immunology Laboratory, ICL</gtr:department><gtr:description>HIV inhibition assays</gtr:description><gtr:id>6F05F10D-BB65-454E-831E-FE3E78050796</gtr:id><gtr:impact>Assays are in progress.</gtr:impact><gtr:partnerContribution>International AIDS Vaccine Initiative provide the expertise in VIA, welcome our student and provided HIV virus stock of various clades</gtr:partnerContribution><gtr:piContribution>We provide samples from clinical trial, a visiting DPhil student and contribute to the cost of the virus inhibition assay (VIA)</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Clinical evaluation of ChAdV63.HIVconsv</gtr:description><gtr:id>A06A5F2C-E1B0-4396-9A7B-916F82E6A04E</gtr:id><gtr:impact>In process.</gtr:impact><gtr:partnerContribution>The GSK partner added a very slow and cumbersome process of approving of the jointly owned candidate vaccine for use in clinical trials. GSK is not interested in an early stage development of HIV vaccines.</gtr:partnerContribution><gtr:piContribution>GSK acquired Okairos, the developer of the ChAdV-63-based vector platform. We are testing the ChAdV63.HIVconsv in four clinical trials: RIVER, PEACHI 04, HIV-CORE 003 and BCN 01.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Weill Cornell Medical College</gtr:department><gtr:description>Antibody Vaccine Development</gtr:description><gtr:id>57E34EA8-6924-4475-BC94-1586966AC29D</gtr:id><gtr:impact>Vaccines under construction</gtr:impact><gtr:partnerContribution>Immunogen BG505 SOSIP
Structural characterization of expressed proteins</gtr:partnerContribution><gtr:piContribution>Construction of new vaccines
Pre-clinical immunogenicity
Optimizing co-delivery of Ab and T cell vaccines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IDT Biologika GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Vacc2020 Development of scalable manufacturing processing form ChAdV and MVA</gtr:description><gtr:id>B855664F-625B-4F47-944C-F76B22CA7E5D</gtr:id><gtr:impact>Application under review</gtr:impact><gtr:partnerContribution>Application under review</gtr:partnerContribution><gtr:piContribution>Application under review</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PaxVax, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Construction of HAdV-4-vectored tHIVconsvX vaccines</gtr:description><gtr:id>70415649-E400-4E44-8B10-C67902FB3D8A</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Construction of candidate vaccines</gtr:partnerContribution><gtr:piContribution>Provision of two tHIVconsvX genes and pre-clinical evaluation</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oregon Health and Science University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Construction of CMV-vectored vaccines and pre-clinical studies</gtr:description><gtr:id>7B829B86-60EC-4001-943A-828A0BC23787</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Construction of CMV.tSIVconsv239 and CMV.tSIVconsvE660 and immunogenicty study in primates</gtr:partnerContribution><gtr:piContribution>Design and provision of two synthetic genes coding for tSIVconsv239 and tSIVconsvE660

Construction of chimp Adenovirus and MAV vectored vaccines carrying the tSIVconsv genes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Construction and preclinical evaluation of ChAdOx1.HIVACAT-T vaccines</gtr:description><gtr:id>D126B198-A146-418E-B7D3-0DC2F7C13FE4</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>Design of the immunogen and pre-clinical testing</gtr:partnerContribution><gtr:piContribution>Design of a synthetic genes and construction of candidate HIV vaccine
 ChAdOx1.HIVACAT-T</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immune Design</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Construction of ID-lentiviral vectors for delivery of conserved mosaic vaccines</gtr:description><gtr:id>2C087054-B8A6-4ADC-9C82-471C9FCCEC45</gtr:id><gtr:impact>Manuscript ready for submission</gtr:impact><gtr:partnerContribution>Immune Design provided lentiviral vectors and inserted our conserved mosaic immunogens gene into them to construct two candidate vaccines</gtr:partnerContribution><gtr:piContribution>We provided designed and provided genes coding forHIV-derived conserved mosaic immunogens and tested the ImmuneDesign-generated vaccines in mice</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GMP manufacture of MVA.tHIVconsv3 and MVA.tHIVconsv4</gtr:description><gtr:id>8AB69BD3-C071-47BF-8BD4-B0FD777BC96A</gtr:id><gtr:impact>When completed, clinical lots of two experimental vaccines</gtr:impact><gtr:partnerContribution>IDT is the manufacturing house
IAVI paid for one rMVA</gtr:partnerContribution><gtr:piContribution>Manufacture of two vaccines for clinical trial use</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Importance of vectors for induction of broadly neutralising anti-HIV antibodies</gtr:description><gtr:id>CD6FB470-A249-441A-8E3B-C759EE372918</gtr:id><gtr:impact>In progress</gtr:impact><gtr:partnerContribution>CHAVI-ID/Barton Haynes (Duke University) provided HIV Envelope genes from sequential HIV isolates with the idea to guide the maturation of antibody affinity.</gtr:partnerContribution><gtr:piContribution>We shall determine the importance of virus vector delivery in heterologous prime-boost regimens for induction of HIV broadly neutralizing antibodies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>International Innovation Article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2E526218-42C5-4399-96C0-195711536359</gtr:id><gtr:impact>Dissemination of science, research and technology

Many more requests from similar journals</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Race for Life</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E412BF79-B0E5-4000-8809-A7AE8EE70E07</gtr:id><gtr:impact>Team building exercise
Websites:
http://www.ccmp.ox.ac.uk/public-engagement
http://www.raceforlifesponsorme.org/kessler-group/eurl.axd/289728e11b02e2478608452b80d5ec5e

Raising awareness for sport as a way to increase health</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NDM Podcast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0323049B-42A4-4E38-84B8-69AA453DDA88</gtr:id><gtr:impact>The podcast is available on the Univesity wensite.

Public understading.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Adjacent Governmant article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>044A7222-172B-4351-9663-DDCC1F6D9C9E</gtr:id><gtr:impact>Articles describing the importance of our research

Invitations to do more</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1031751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DCS</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J008605/1</gtr:fundingRef><gtr:id>E1209613-E751-4DB6-8DBC-76116B5C204D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>GMP manufacture</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>International AIDS Vaccine Initiative (IAVI)</gtr:fundingOrg><gtr:fundingRef>SOW4 and SOW5</gtr:fundingRef><gtr:id>4D8BB953-314C-4ACF-B3A6-98AFD4517DB6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>CHAVI-ID (Duke)</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>0209B651-2932-486B-84CE-A9596C744F6F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership (EDCTP)</gtr:department><gtr:description>EDCTP Strategic Primer</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>SP.2011.41304.002</gtr:fundingRef><gtr:id>35B19802-D28E-438F-8C5E-0FDF2369F79D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC RIVER DCS</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L00528X/1</gtr:fundingRef><gtr:id>82EA5358-0551-407C-9314-9055F8054BBC</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>FP7</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>305632</gtr:fundingRef><gtr:id>7363928B-C363-4602-B690-9C5232EB6A45</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22900000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EAVI2020</gtr:description><gtr:end>2021-10-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>22BDE414-6D19-474D-82A2-A54F86B3A1A0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISSF Wellcome Trust</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>39ED3632-F420-427C-A11D-5A023FABBC2E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We shall test novel potent T cell vaccines delivered in combination to safely induce anti-HCV and anti-HIV T cell immunity simultaneously in a single host.</gtr:description><gtr:id>F4E5CC3A-3725-4614-8640-E1B421FDF1BE</gtr:id><gtr:impact>Clinical trial is recruiting.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PEACHI 04</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first assessment of enhancement of DNA vaccination by serum amyloid component B depletion by CPHPC iv infusion in man
Primarily supported by an MRC award to Professor Sir Mark Pepys</gtr:description><gtr:id>28ED23DE-0E47-497F-9971-20FBD8FF514E</gtr:id><gtr:impact>Proof of concept trial</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV-CORE 003</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>EudraCT 201200405211</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>http://www.croiconference.org/sessions/viral-control-induced-hivconsv-vaccines-romidepsin-early-treated-individuals</gtr:description><gtr:id>A8F94CBC-C491-4C2B-9211-3BED8B814E97</gtr:id><gtr:impact>Early times</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>BCN 02 - ROMI</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://www.croiconference.org/sessions/viral-control-induced-hivconsv-vaccines-romidepsin-early-treated-individuals</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first evaluation of the conserved region vaccines delivered by DNA (electroporated), MVA and HAdV-35 in healthy HIV-uninfected adults in Nairobi, Kenya
Prophylactic, not therapeutic vaccine
Trial is in not completed 
Mainly supported by EDCTP award</gtr:description><gtr:id>25809131-B3BE-4E7B-A59B-EF4D2A39F89D</gtr:id><gtr:impact>The first test of these vaccine in Africa</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV-CORE 004</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>Ref no. PPB/ECCT/13/07/01/2013/(100) (Kenya regulator)</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>HIVconsv is a universal T cell immunogen focusing T cells responses on the conserved, i.e. common regions of the HIV-1 proteome. HIVconsv was delivered by DNA, modified vaccinia virua Ankara (MVA) and chimpanzee adenovirus serotype 63 (ChAdV-63) to healthy uninfected individual in UK. It is prophylactic, not therapeutic vaccine.</gtr:description><gtr:id>1DA4B047-F3AF-4EA8-B35E-584291937EA0</gtr:id><gtr:impact>The first use of HIV vaccine based on conserved regions of the HIV-1 proteome to healthy individuals, the first use of ChAdV-63 for HIV vaccines, the first use of ChAdV-63 prime-MVA boost and DNA-ChAdV-63-MVA regimens for HIV in man</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HIV-CORE 002</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>EudraCT 2010-018439-16</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first use of conserved region vaccine MVA.HIVconsv in HIV-infected individuals in UK
Primarily supported by a MRC award to Dr Lucy Dorrell</gtr:description><gtr:id>ABCC2AA1-0017-4D3D-A08D-AC8242A9CDFE</gtr:id><gtr:impact>The first use of conserved region vaccine in man</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>HIV-CORE 001</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>EudraCT 2009-012662-31</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Assessment of decreasing latent HIV pool by reactivation and vaccination</gtr:description><gtr:id>FF98BE21-0ECA-4BC8-A322-A678514E80B4</gtr:id><gtr:impact>Testing in process</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RIVER</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The first immunogenicity evaluation of ChAdV63.HIVconsv prime-MVA.HIVconsv boost vaccine regimen delivering conserved regions of the HIV-1 proteome in HIV-1-infected individuals early on HAART</gtr:description><gtr:id>2B033806-5BEF-4820-B73A-BB6E31CEF7BF</gtr:id><gtr:impact>The fist therapeutic use of this vaccine regimen in HIV-infected individuals</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>BCN 01</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>EudraCT 2011-000846-39</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Methodology for identifying HLA class i-associated peptides derived from intracellular pathogens</gtr:description><gtr:id>EF9A7DC1-51E8-4D33-A4FD-D0A5A6950B0E</gtr:id><gtr:impact>Publications in preparation or submitted and lots of interest from pathogens other than HIV</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Elution and analysis of HLA class I-associated peptidomes</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>2nd generation improved HIVconsv vaccines
Improved immunogens with increased global coverage of HIV variants</gtr:description><gtr:id>0CEF0472-22BC-42EA-A625-46CF4386E855</gtr:id><gtr:impact>Under construction</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>2nd generation HIVconsv vaccines</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Vaccines aiming at induction of broadly neutralizing anti-HIV antibody
Genes for modified BG505 Env immunogens were inserted into DNA, MVA and ChAdV</gtr:description><gtr:id>7BFAB476-CDD8-449A-9769-FE73C7D106FC</gtr:id><gtr:impact>Experiments ongoing</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HIV vaccines inducing antibodies</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1D8DD001-EDB9-4498-9545-D50DD998AA1F"><gtr:id>1D8DD001-EDB9-4498-9545-D50DD998AA1F</gtr:id><gtr:title>A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92e29644a267ffb27cceb67604bc0126"><gtr:id>92e29644a267ffb27cceb67604bc0126</gtr:id><gtr:otherNames>Mothe B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/833A4829-2FC5-4A48-BBDA-A88B17B2FB6A"><gtr:id>833A4829-2FC5-4A48-BBDA-A88B17B2FB6A</gtr:id><gtr:title>Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91a4a8d3630e6be3253b4d9100f94e3b"><gtr:id>91a4a8d3630e6be3253b4d9100f94e3b</gtr:id><gtr:otherNames>Abdul-Jawad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0629438E-889E-45FC-B656-BA025FD8C5D8"><gtr:id>0629438E-889E-45FC-B656-BA025FD8C5D8</gtr:id><gtr:title>Infant Neutropenia Associated with Breastfeeding During Maternal Antiretroviral Treatment for Prevention of Mother-to-Child Transmission of HIV</gtr:title><gtr:parentPublicationTitle>Retrovirology: Research and Treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d298ff4ccafb616a9accbf8dc04f80e5"><gtr:id>d298ff4ccafb616a9accbf8dc04f80e5</gtr:id><gtr:otherNames>Njuguna</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30C85400-D4EE-47D7-9D07-B068430F329E"><gtr:id>30C85400-D4EE-47D7-9D07-B068430F329E</gtr:id><gtr:title>Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/76a77438793da366546ba3f51da666b2"><gtr:id>76a77438793da366546ba3f51da666b2</gtr:id><gtr:otherNames>Mor?n-L?pez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F7BCC60-5F1D-4172-8CCC-D3F74022C954"><gtr:id>0F7BCC60-5F1D-4172-8CCC-D3F74022C954</gtr:id><gtr:title>Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0527f3251154b89261e24b442c909f60"><gtr:id>0527f3251154b89261e24b442c909f60</gtr:id><gtr:otherNames>Knudsen ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A72F91A-2157-4AED-876E-6B3EB895BB39"><gtr:id>1A72F91A-2157-4AED-876E-6B3EB895BB39</gtr:id><gtr:title>Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97f7291a65144b6159945ac5510fe4f1"><gtr:id>97f7291a65144b6159945ac5510fe4f1</gtr:id><gtr:otherNames>Ahmed T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A9D428E-307A-47C9-BECF-2453EA466B56"><gtr:id>1A9D428E-307A-47C9-BECF-2453EA466B56</gtr:id><gtr:title>Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/10fdc3a18782fadea3984d32a070baa5"><gtr:id>10fdc3a18782fadea3984d32a070baa5</gtr:id><gtr:otherNames>Hayton EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB12A09F-CF7A-4203-B2F6-5EDD968365F3"><gtr:id>DB12A09F-CF7A-4203-B2F6-5EDD968365F3</gtr:id><gtr:title>Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73C1AD31-6BCC-4AD6-AFB3-956E580FF352"><gtr:id>73C1AD31-6BCC-4AD6-AFB3-956E580FF352</gtr:id><gtr:title>Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Methods &amp; clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b6d6cfff7eac8005bf946988c16f2a92"><gtr:id>b6d6cfff7eac8005bf946988c16f2a92</gtr:id><gtr:otherNames>Saubi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2329-0501</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7237017-09D3-478B-A3EB-42D89A1EC40F"><gtr:id>B7237017-09D3-478B-A3EB-42D89A1EC40F</gtr:id><gtr:title>Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24ACD441-714F-4D61-BCBE-38591EEF2CEF"><gtr:id>24ACD441-714F-4D61-BCBE-38591EEF2CEF</gtr:id><gtr:title>Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/215a458258dd460674f9cc98e1c2b628"><gtr:id>215a458258dd460674f9cc98e1c2b628</gtr:id><gtr:otherNames>Hancock G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46179DA0-0047-459C-9D6B-75588AB7291F"><gtr:id>46179DA0-0047-459C-9D6B-75588AB7291F</gtr:id><gtr:title>Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.</gtr:title><gtr:parentPublicationTitle>Immunity, inflammation and disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a1fb2f5be500cb027b90c8289746892c"><gtr:id>a1fb2f5be500cb027b90c8289746892c</gtr:id><gtr:otherNames>Borthwick NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-4527</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DAD12BF3-6D74-4720-8BAE-62FD38B97E90"><gtr:id>DAD12BF3-6D74-4720-8BAE-62FD38B97E90</gtr:id><gtr:title>Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f02b9025275703fa69f602064c14a874"><gtr:id>f02b9025275703fa69f602064c14a874</gtr:id><gtr:otherNames>Ternette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDD28458-B79F-4B0D-ABE2-4D850A849DEE"><gtr:id>EDD28458-B79F-4B0D-ABE2-4D850A849DEE</gtr:id><gtr:title>Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D678E271-FED7-449B-A3D9-EF39DE5B4443"><gtr:id>D678E271-FED7-449B-A3D9-EF39DE5B4443</gtr:id><gtr:title>Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03A242B0-684E-4479-BC98-43210F12579C"><gtr:id>03A242B0-684E-4479-BC98-43210F12579C</gtr:id><gtr:title>Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f02b9025275703fa69f602064c14a874"><gtr:id>f02b9025275703fa69f602064c14a874</gtr:id><gtr:otherNames>Ternette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1EFA688-BEC9-41A2-84DA-7F74337C6A02"><gtr:id>F1EFA688-BEC9-41A2-84DA-7F74337C6A02</gtr:id><gtr:title>DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80ea5f2a56653c00efb611ec5b24e194"><gtr:id>80ea5f2a56653c00efb611ec5b24e194</gtr:id><gtr:otherNames>Koopman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC219684-3CCF-4E01-97A1-6614010CF8F4"><gtr:id>AC219684-3CCF-4E01-97A1-6614010CF8F4</gtr:id><gtr:title>Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9077CA88-B14A-4778-8E70-50A5914F56CA"><gtr:id>9077CA88-B14A-4778-8E70-50A5914F56CA</gtr:id><gtr:title>Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/411B2766-3954-46AF-AF58-E3B5D1773C55"><gtr:id>411B2766-3954-46AF-AF58-E3B5D1773C55</gtr:id><gtr:title>Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b6d6cfff7eac8005bf946988c16f2a92"><gtr:id>b6d6cfff7eac8005bf946988c16f2a92</gtr:id><gtr:otherNames>Saubi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59412479-D527-4F4D-96AD-1BE8863B1092"><gtr:id>59412479-D527-4F4D-96AD-1BE8863B1092</gtr:id><gtr:title>Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fd46411c37ebf6a7f879374f9fe427a2"><gtr:id>fd46411c37ebf6a7f879374f9fe427a2</gtr:id><gtr:otherNames>Clutton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6DC7C9C1-D4DF-498B-96CF-57D6BECF42B9"><gtr:id>6DC7C9C1-D4DF-498B-96CF-57D6BECF42B9</gtr:id><gtr:title>A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.</gtr:title><gtr:parentPublicationTitle>Journal of translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92e29644a267ffb27cceb67604bc0126"><gtr:id>92e29644a267ffb27cceb67604bc0126</gtr:id><gtr:otherNames>Mothe B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1479-5876</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF47720F-F49D-4CD1-B2CD-3DFBCD6AE2B6"><gtr:id>DF47720F-F49D-4CD1-B2CD-3DFBCD6AE2B6</gtr:id><gtr:title>A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/16b26d8a504fa824577d7c9a7ea4c286"><gtr:id>16b26d8a504fa824577d7c9a7ea4c286</gtr:id><gtr:otherNames>Str?m P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/14064FC6-CC3D-4587-95C1-C9C49575E2C1"><gtr:id>14064FC6-CC3D-4587-95C1-C9C49575E2C1</gtr:id><gtr:title>Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fd46411c37ebf6a7f879374f9fe427a2"><gtr:id>fd46411c37ebf6a7f879374f9fe427a2</gtr:id><gtr:otherNames>Clutton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001757</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>